Business & Market Trends ATA NEXUS 2026 Highlights Telehealth’s Regulatory Challenges

Why It Matters

Regulatory and payment complexities threaten the profitability and scalability of telehealth, limiting patient access and slowing industry growth.

Key Takeaways

• State‑by‑state licensure and prescribing rules create operational bottlenecks.
• AI tools demand governance frameworks and patient disclosure to meet compliance.
• New CPT codes enable remote therapeutic monitoring but increase documentation load.
• CMS value‑based models favor large telehealth networks, challenging small practices.

Pulse Analysis

The ATA NEXUS 2026 summit laid bare the regulatory maze that now defines telehealth expansion in the United States. While broadband and video platforms have matured, clinicians still confront a patchwork of state licensure requirements, divergent prescribing statutes, and varying telehealth registration models. This inconsistency forces providers to either limit their geographic footprint or invest in costly multi‑state compliance infrastructures. The lingering uncertainty around the Ryan Haight Act waivers and DEA exemptions only deepens the risk, prompting many organizations to pause entry into markets where state rules could later reverse.

Artificial intelligence is rapidly becoming a double‑edged sword for digital health firms. On one hand, large‑language models can scan legislative updates, flag payer policy shifts, and streamline clinical decision support, promising efficiency gains for remote‑care operations. On the other, regulators are tightening expectations around AI transparency, patient consent, and algorithmic bias mitigation. The conference urged providers to embed formal AI governance—documented usage policies, continuous risk assessments, and legal oversight—into their practice workflows. Failure to do so could trigger audits, liability exposure, and erosion of patient trust.

Reimbursement uncertainty remains the final hurdle to a financially viable telehealth ecosystem. Recent CPT revisions introduce remote therapeutic monitoring and AI‑enabled diagnostic codes, expanding billing options but also demanding granular documentation to satisfy auditors. Simultaneously, CMS’s value‑based initiatives such as the ACCESS model tie payments to patient outcomes and digital engagement, a structure that benefits large, data‑rich telehealth networks while marginalizing solo practitioners. Without clearer federal guidance and streamlined state policies, the industry risks a bifurcated future where only well‑capitalized players can sustain growth, leaving many patients without virtual‑care alternatives.